Urosepsis Due to Fluoroquinolone-Resistant Escherichia coli after Ultrasonographic-Guided Transrectal Implantation of Fiducial Markers

Liss M.A. , Chang A. , Santos R. . Prevalence and significance of fluoroquinolone resistant Escherichia coli in patients undergoing transrectal ultrasound guided prostate needle biopsy. J Urol. 2011; 185(4): 1283–1288.

Mosharafa A.A. , Torky M.H. , Said W.M. . Rising incidence of acute prostatitis following prostate biopsy: fluoroquinolone resistance and exposure is a significant risk factor. Urology. 2011; 78(3): 511–514.

Sieber P.R. , Rommel F.M. , Agusta V.E. . Antibiotic prophylaxis in ultrasound guided transrectal prostate biopsy. J Urol. 1997; 157(6): 2199–2200.

Feliciano J. , Teper E. , Ferrandino M. . The incidence of fluoroquinolone resistant infections after prostate biopsy: are fluoroquinolones still effective prophylaxis? J Urol. 2008; 179(3): 952–955.

Zaytoun O.M. , Vargo E.H. , Rajan R. . Emergence of fluoroquinolone-resistant Escherichia coli as cause of postprostate biopsy infection: implications for prophylaxis and treatment. Urology. 2011; 77(5): 1035–1041.

Zervos M.J. , Hershberger E. , Nicolau D.P. . Relationship between fluoroquinolone use and changes in susceptibility to fluoroquinolones of selected pathogens in 10 United States teaching hospitals, 1991-2000. Clin Infect Dis. 2003; 37(12): 1643–1648.

Karlowsky J.A. , Jones M.E. , Thornsberry C. . Trends in antimicrobial susceptibilities among Enterobacteriaceae isolated from hospitalized patients in the United States from 1998 to 2001. Antimicrob Agent Chemother. 2003; 47(5): 1672–1680.

Patel U. , Dasgupta P. , Amoroso P. . Infection after transrectal ultrasonography-guided prostate biopsy: increased relative risks after recent international travel or antibiotic use. BJU Int. 2011; 109(12): 1781–1785.

Edge S.B. , Byrd D.R. , Compton C.C. eds. AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer-Verlag; 2010.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer, v.4.2011. www.nccn.org. Accessed December 26, 2012.

Thompson I. , Thrasher J.B. , Aus G. . Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007; 177(6): 2106–2131.

Peeters S.T. , Heemsbergen W.D. , Koper P.C. . Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol. 2006; 24(13): 1990–1996.

Dehnad H. , Nederveen A.J. , van der Heide U.A. . Clinical feasibility study for the use of implanted gold seeds in the prostate as reliable positioning markers during megavoltage irradiation. Radiother Oncol. 2003; 67(3): 295–302.

Crook J.M. , Raymond Y. , Salhani D. . Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol. 1995; 37(1): 35–42.

Ulises J. , Escudero J. , Ramos de Campos M. . Insertion of intraprostate gold fiducial markers. Int J Nephrol Urol. 2010; 2: 265–272.

Langenhuijsen J.F. , van Lin E.N. , Kiemeney L.A. . Ultrasound-guided transrectal implantation of gold markers for prostate localization during external beam radiotherapy: complication rate and risk factors. Int J Radiat Oncol Biol Phys. 2007; 69(3): 671–676.

Obedian E. , Kapoor D.A. , Olsson C.A. . The risk of urosepsis in patients undergoing fiducial marker placement for image guided radiation therapy (IGRT) of prostate cancer. Int J Radiat Oncol Biol Phys. 2008; 72: S324–S325.

Young J.L. , Liss M.A. , Szabo R.J. . Sepsis due to fluoroquinolone-resistant Escherichia coli after transrectal ultrasound-guided prostate needle biopsy. Urology. 2009; 74(2): 332–338.

Wolf JS Jr , Bennett C.J. , Dmochowski R.R. . Best practice policy statement on urologic surgery antimicrobial prophylaxis. J Urol. 2008; 179(4): 1379–1390.

Shandera K.C. , Thibault G.P. , Deshon GE Jr . Variability in patient preparation for prostate biopsy among American urologists. Urology. 1998; 52(4): 644–646.

Heidenreich A. , Bellmunt J. , Bolla M. . EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol. 2011; 59(1): 61–71.

Liss M.A. , Peeples A.N. , Peterson E.M. . Detection of fluoroquinolone-resistant organisms from rectal swabs by use of selective media prior to a transrectal prostate biopsy. J Clin Microbiol. 2011; 49(3): 1116–1118.

Otrock Z.K. , Oghlakian G.O. , Salamoun M.M. . Incidence of urinary tract infection following transrectal ultrasound guided prostate biopsy at a tertiary-care medical center in Lebanon. Infect Control Hosp Epidemiol. 2004; 25(10): 873–877.

Fridkin S.K. , Hill H.A. , Volkova N.V. . Temporal changes in prevalence of antimicrobial resistance in 23 US hospitals. Emerg Infect Dis. 2002; 8(7): 697–701.